A $74B Market With
Two FDA Approvals

A $74B botanical drug market has produced only 2 FDA botanical drug approvals — and the gap isn't a coincidence. FDA botanical NDAs require consistent, well-characterized extracts with rigorous pharmacological documentation: evidence that doesn't exist in unified form today. Traditional medicine knowledge sits in siloed databases: TCM in TCMSP, Ayurveda in IMPPAT, Western herbalism scattered across journals. Researchers stitch together 5–10 disconnected tools to go from plant to drug target — before a single preclinical study begins. 3IT Phyto addresses the data layer: unifying the ethnopharmacological evidence base that rigorous botanical drug development requires. Meanwhile, AI drug discovery investment has exploded to $2.9B (2025), heading to $13.4B by 2035 — but almost entirely focused on synthetic molecules. Botanical drug discovery is the most under-served slice of that market: plant chemistry's structural diversity is ignored by platforms built for de novo synthesis.

3IT Phyto sits at the intersection: the first cross-tradition platform that unifies ethnopharmacological data from TCM, Ayurveda, Unani, and Western herbalism into a single computational pipeline. With 768K compounds, 28K plants, and 24.4M literature linkages already curated, the dataset itself is a defensible moat. Our pipeline filters 940K compound–target interactions to 155K high-confidence pairs — 1 in 6 clears the threshold — selectivity no public database delivers end-to-end. No competitor offers both the cross-tradition data breadth and the end-to-end drug discovery workflow.